Evaluation of IL‑17A Expressions in High‑Grade Glial Tumors Receiving Radiotherapy

Creative Commons License

Karaca F., Keskin S., Menteş S., Ökten A. İ., Çavuş G., Arslan A., ...More

NIGERIAN JOURNAL OF CLINICAL PRACTICE, vol.25, pp.522-588, 2022 (SCI-Expanded)

  • Publication Type: Article / Article
  • Volume: 25
  • Publication Date: 2022
  • Doi Number: 10.4103/njcp.njcp_1408_21
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.522-588
  • Van Yüzüncü Yıl University Affiliated: Yes


In this study, we aimed to investigate the interleukin‑17A (IL‑17A) levels in patients with high-grade glial tumors before receiving radiotherapy, immediately after radiotherapy, and 3 months after radiotherapy. Patients and Methods: A total of 33 patients who applied to Adana City Training and Research Hospital, Department of Radiation Oncology between December 2016 and May 2018 was included in this study. A total of three blood samples was taken from each patient to assess IL‑17A levels before and after radiotherapy and 3 months after the completion of radiotherapy. Results: The differences in IL‑17A levels between genders were not statistically significant. IL‑17A levels progressively decreased after the radiotherapy and 3 months after the radiotherapy as compared to the levels before radiotherapy. However, this was not statistically significant. IL‑17A levels in the non‑surviving patients were high before and after radiotherapy as compared to the surviving ones, but this was also not statistically significant. Conclusion: As compared to the period before radiotherapy, IL‑17A levels tend to decrease in the period of acute and chronic phases of radiotherapy in all patient groups.